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Abstract 
Death associated protein kinase (DAPK)-related apoptosis-inducing protein kinase (DRAK)-1 is a 
positive apoptosis regulator. However, the molecular mechanisms underlying the DRAK1-mediated 
apoptotic pathway remain unclear. In this study, we demonstrated the intracellular localization and 
binding partners of DRAK1. In human osteosarcoma cell line U2OS cells, DRAK1 was mainly 
localized in the nucleus and translocated outside the nucleus through Ser395 phosphorylation by protein 
kinase C. In the nucleus, DRAK1 associated with tumor suppressor p53 and positively regulated p53 
transcriptional activity in response to DNA-damaging agent cisplatin. On the other hand, DRAK1 
interacted with the mitochondrial inner-membrane protein, adenine nucleotide translocase (ANT)-2, an 
anti-apoptotic oncoprotein, outside the nucleus. These findings suggest that DRAK1 translocates in 
response to stimuli and induces apoptosis through its interaction with specific binding partners, p53 
and/or ANT2. 
 
Abbreviations: DAPK, death associated protein kinase; DRAK, DAPK-related apoptosis-inducing 
protein kinase; ANT, adenine nucleotide translocase; VDAC, voltage-dependent anion channel; NLS, 
nuclear localization signal; PKC, protein kinase C; PMA, phorbol myristate acetate. 
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1. Introduction 
Death associated protein kinase (DAPK)-related apoptosis-inducing protein kinase (DRAK) 1 is a 
member of the DAPK family comprising five types: DAPK1-DAPK3, DRAK1, and DRAK2 [1]. 
These family members have the highest homology in their Ser/Thr kinase domains at the N terminus, 
whereas their C-terminal regions largely differ and contain unique domains. DAPK1, which is the 
most studied of the family members, has a long sequence at its C terminus, comprising a 
calmodulin-binding domain, eight ankyrin-binding repeats, a ROC-COR domain, and a C-terminal 
death domain. These unique domains affect its function and localization through interaction with 
several protein partners [2, 3]. For example, the death domain mediates an interaction with ERK, and 
ERK causes an increase in DAPK1 activity by phosphorylating DAPK1 [2]. Similarly, many studies 
report significant relationships between specific binding proteins and the physiological functions of 
the other DAPK family members [1, 4]. However, although DRAK1 has been known to be exclusively 
localized in the nucleus and induce apoptosis [5], the molecular mechanism of the DRAK1-mediated 
apoptotic signaling pathway, including its binding partners, remains to be elucidated. 
A recent study showed that DRAK1 is a direct target gene of tumor suppressor p53 [6]. p53 is 
activated by various cell stresses, such as DNA damage and activated oncogenes, thereby inducing the 
transcription of genes that promote cell death and growth arrest (e.g., p21, the proapoptotic protein 
Bax) and inhibiting the transcription of several cell-survival genes (e.g., survivin, the antiapoptotic 
protein Bcl-2) [7]. DRAK1 was upregulated by cisplatin, a DNA-damaging agent in various cell lines 
in a p53-dependent manner, and p53 directly bound to an upstream element in DRAK1 [6]. In response 
to DNA damage, p53 function is regulated by phosphorylation at multiple sites. Casein kinase 2 (CK2) 
phosphorylates p53 at Ser392, thereby enhancing DNA binding ability [8]. In addition, DAPK1 
phosphorylates p53 at Ser23 (Ser23 in mice and Ser20 in humans), and p53 transcriptionally regulates 
apoptosis-promoting genes, such as Bax [3]. 
Proapoptotic proteins Bax and Bad can regulate the channel activity of mitochondrial adenine 
nucleotide translocases (ANTs) that control the mitochondrial apoptosis pathway [9, 10]. The ANT 
family comprises four members, ANT1-ANT4, which are abundant in the inner mitochondrial 
membrane, catalyze the exchange of ADP/ATP, and regulate mitochondrial membrane permeability 
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together with a voltage-dependent anion channel (VDAC) [9, 11]. The expressions of ANT isoforms 
differ depending on the cell type. ANT1 is abundantly expressed in terminally differentiated cells, 
whereas ANT2 is highly expressed in undifferentiated cells with proliferating ability. Importantly, 
ANT2 expression is higher than that of ANT1 in several types of human cancer cells. ANT1 plays a 
proapoptotic role, whereas ANT2 functions as an antiapoptotic factor in cancer cells. 
In this study, we investigated the mechanism of intracellular localization of DRAK1. DRAK1 
was localized in the nucleus by two nuclear localization signal (NLS) sequences, and translocated 
outside the nucleus in response to stimuli that activate protein kinase C (PKC). Furthermore, we 
identified p53 and ANT2 as novel DRAK1-interacting partners. DRAK1 positively regulated p53 
transcriptional activity in cisplatin-treated human osteosarcoma. These findings suggest that 
subcellular localization of DRAK1 through interaction with specific binding partners may be 
important for DRAK1 signaling. 
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2. Materials and methods 
2.1. Antibodies 
Antibody against DRAK1 was purchased from Novus Biologicals. Anti-p53, anti-phospho-p53 
(Ser-392), and anti-phospho-(Ser) PKC substrate antibodies were from Cell Signaling Technology, 
and anti-GST and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were from 
Wako. Anti-Strep antibody was purchased from Qiagen, and anti-FLAG antibody was from 
Sigma-Aldrich. 
 
2.2. Plasmid construction 
Full-length human DRAK1, DRAK2, and ANT2 cDNAs were cloned by PCR using specific 
primers. The DRAK1 and DRAK2 cDNAs were subcloned into a mammalian expression vector, 
pEXPR-IBA105 (N-terminal Strep tag) (IBA). The ANT2 cDNA was inserted in-frame into 
pCMV-3Tag-3A vector (C-terminal 3x FLAG tag) (Agilent Technologies). Site-directed mutagenesis 
was performed using the PrimeSTAR Mutagenesis Basal Kit (TaKaRa).  
 
2.3. Cell culture, transfection, and RNA interference 
U2OS, HEK293T, and COS-7 cells were cultured in DMEM supplemented with 10% FBS, 100 
units/ml penicillin, and 100 μg/ml streptomycin. Transfection and RNA interference were performed 
using Lipofectamine 2000 (Thermo Fisher Scientific). The synthetic siRNA oligonucleotide for 
DRAK1 was purchased from Sigma (ID# SASI_Hs01_00136992). MISSION siRNA Universal 
Negative Control #1 (Sigma) was used as the negative control. Cisplatin was dissolved in 100% 
N,N-dimethyl formamide (DMF), and the final concentration of DMF in the culture medium was 
0.1%.  
 
2.4. Immunofluorescence analysis. 
Immunofluorescence analysis was performed as previously described [12]. In brief, U2OS cells 
were transfected with various expression plasmids in the presence or absence of mitochondria-targeted 
mKeima-Red expression plasmid, pMT-mKeima-Red (MBL). After 24 hours, cells were fixed, 
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permeabilized, and then blocked in 5% BSA. Cells were incubated with anti-Strep or anti-GST 
antibodies, followed by incubation with anti-IgG directly conjugated to AlexaFluor 488 or 555 
(Thermo Fisher Scientific). Fluorescent images were obtained using an IN Cell Analyzer 6000 system 
(GE Healthcare). 
 
2.5. Protein identification by MALDI-TOF MS  
HEK293T cells were transfected with Strep-DRAK1 or DRAK2 expression plasmids. After 24 
hours, the cells were scraped in cell lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% 
Nonidet P-40, 1 mM EDTA, 10 μg/ml leupeptin, and 10 μg/ml aprotinin). After centrifugation, the 
supernatants were incubated with Strep-Tactin Sepharose (IBA). After the beads were washed, the 
bound proteins were eluted with SDS-loading buffer and resolved by 12% SDS-PAGE, followed by 
silver staining. The subsequent protocol has previously been described [4].  
 
2.6. Pull-down assay 
HEK293T and COS-7 cells transfected with N-terminal Strep-tagged or GST-fused DRAK1 
together with C-terminal FLAG-tagged ANT2 were scraped in lysis buffer, and cell lysates were 
incubated with Strep-Tactin or Glutathione Sepharose (GE Healthcare) overnight at 4°C by rotation. 
The bound proteins were analyzed by immunoblot analysis using anti-FLAG antibody. 
 
2.7. Luciferase reporter assay 
U2OS cells were plated at a density of 2 × 104 cells in a 24-well plate. After 24 hours, the cells 
were transfected with negative control siRNA or DRAK1 siRNA. Six hours later, cells were 
transfected with pGL4.38 [luc2P/p53 RE/Hygro] (Promega), which contains two tandem repeats of a 
p53 response element, together with pCMV-β-gal for 24 hours. After treatment with 30 μM cisplatin 
for 24 hours, the cells were lysed with cell culture lysis reagent (Promega) and subjected to luciferase 
reporter assay. Luciferase and β-galactosidase activities were measured as previously described [13].  
 
2.8. Statistical analysis 
7 
 
All experiments were performed multiple times to confirm their reproducibility. One 
representative set of data was shown in the figures. The results were quantified using Image J software 
(NIH). Data were expressed as the mean ± standard error, and statistical analysis was performed by 
one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test using GraphPad Prism 
(GraphPad Software).  
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3. Results 
3.1. Subcellular localization of DRAK1 in U2OS cells 
A previous study demonstrated that DRAK1 is exclusively localized in the nucleus of COS-7 
cells [5]. However, a recent report showed that subcellular localization of DRAK1 is dependent on cell 
type, and that DRAK1 is localized in the cytoplasm but not the nucleus in head and neck squamous 
cell carcinoma cell lines [14]. Therefore, we first examined the subcellular localization of the 
N-terminal Strep-tagged DRAK1 wild type (Strep-DRAK1-WT) in human osteosarcoma cell line 
U2OS cells. Immunostaining analysis revealed that Strep-DRAK1-WT was localized mainly in the 
nucleus and only slightly localized in the cytoplasm in U2OS cells (Fig. 1B (i)). Similar results were 
obtained in HeLa cells (data not shown). Since DRAK1 was localized mainly in the nucleus, we 
examined whether the NLS sequence exists in the DRAK1 amino acid sequence. DRAK1 contains 
two patches of basic residues (Arg or Lys), one in the catalytic domain (93RKRRKG) and one near the 
C terminus (395SKRFK) (Fig. 1A). Thus, we constructed two mutants, DRAK1-K94A/R95A/R96A 
and DRAK1-K396A/R397A, in which each of the putative NLS sites was replaced by Ala, and 
examined their subcellular localization. As shown in Figs. 1B (ii) and (iii), the mutants were scarcely 
observed in the nucleus and both localized in the cytoplasm, considering that these sequences are 
required for nuclear localization. The sequence near the C terminus (395SKRFK) matched the 
consensus phosphorylation motif for PKC (pS-X-(R/K)). Because of the possibility that Ser395 
immediately adjacent to NLS at the C terminus might mask its function when phosphorylated, we 
created the phosphomimic mutant DRAK1-S395D, in which Ser395 was replaced with Asp, and 
examined its intracellular localization. DRAK1-S395D was also found in the cytoplasm but not in the 
nucleus (Fig. 1B (iv)). Furthermore, we investigated whether two PKC activators, phorbol myristate 
acetate (PMA) and 1-oleoyl-2-acetyl-sn-glycerol (OAG), influence DRAK1’s subcellular localization. 
U2OS cells expressing Strep-DRAK1-WT or -S395A were treated with either PMA or OAG. Both 
PKC activators induced the translocation of Strep-DRAK1-WT into the cytoplasm, including the 
mitochondria, and exhibited colocalization with a mitochondrial marker (Fig. 1C, data not shown). On 
the contrary, phospho-null mutant S395A, in which the putative PKC phosphorylation site was 
replaced by Ala, failed to translocate into the cytoplasm in response to PKC stimulation. In addition, 
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we examined the phosphorylation of Strep-DRAK1 in U2OS cells treated with PMA. After 
stimulation with PMA, the cell lysates were subjected to a Strep pull-down assay and immunoblotting 
with anti-phospho-(Ser) PKC substrate antibody. As shown in Fig. 1D, DRAK1-WT was 
phosphorylated after PMA stimulation, whereas DRAK1-S395A was not. These results suggest that 
DRAK1 is normally localized primarily in the nucleus, but it translocates outside the nucleus after 
stimulation accompanied by PKC activation. 
 
3.2. Regulation of p53 transcriptional activity by DRAK1 in cisplatin-treated U2OS cells 
A previous study showed that the expression of DRAK1 is induced by cisplatin, a 
DNA-damaging agent that induces cell death primarily by apoptosis, in testicular cancer cells in a 
p53-dependent manner [6]. Cisplatin has also induced DRAK1 expression in U2OS cells that express 
endogenous wild-type p53. On the other hand, p53 activity is shown to be regulated by 
phosphorylation at multiple sites, including Ser392 [7]. Because Strep-DRAK1-WT and FLAG-p53 
were colocalized in the nucleus (Fig. 2A), we hypothesized that DRAK1 might also regulate p53 
transcriptional activity. To test this hypothesis, we first examined whether DRAK1 interacts with p53. 
U2OS cells were transfected with Strep-DRAK1-WT, and the cell lysates were subjected to the 
pull-down assay and immunoblotting with an anti-p53 antibody. Although p53 was endogenously 
expressed in U2OS cells, no interaction between DRAK1-WT and p53 was observed under normal 
conditions (Fig. 2B). However, when the cells were treated with cisplatin, the level of p53 protein was 
increased, and p53 accordingly interacted with DRAK1-WT. Conversely, p53 did not bind to the 
phosphomimic mutant S395D. Because DRAK2 has an amino acid sequence highly similar to that of 
DRAK1 and is also localized in the nucleus [15], we investigated whether it could also interact with 
p53. Although DRAK1 bound to p53 in cisplatin-treated cells, DRAK2 did not (Fig. 2C). These 
results suggest that DRAK1 specifically interacts with p53 in the nucleus in response to DNA damage. 
We also examined the endogenous expression of DRAK1 in cisplatin-treated U2OS cells. 
DRAK1 was not normally expressed in U2OS cells, but cisplatin dose-dependently upregulated 
DRAK1 expression (Fig. 2D). Importantly, the phosphorylation of p53 at Ser392, which is known to 
enhance sequence-specific DNA binding [8], was significantly increased after treatment with 30 μM 
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cisplatin. Thus, we assessed whether DRAK1 affects the phosphorylation of p53 at Ser392 by 
knockdown analysis using siRNA. DRAK1 expression induced by cisplatin was efficiently reduced by 
DRAK1 siRNA (Fig. 2D). Although the overall amount of p53 remained the same, DRAK1 siRNA 
significantly reduced the level of p53 phosphorylation at Ser392. Because Ser392 phosphorylation 
enhances DNA binding ability, we subsequently examined the effect of DRAK1 on p53 transcriptional 
activity. U2OS cells were transfected with the luciferase reporter construct containing two copies of 
the p53-responsive element. After treatment with cisplatin, luciferase and β-galactosidase activities 
were determined. Cisplatin increased p53 promoter activity, and which was significantly reduced by 
DRAK1 knockdown (Fig. 2E). A similar result was obtained using another DNA-damaging agent, 
etoposide (data not shown). These results demonstrated that DRAK1 positively regulates p53 
transcriptional activity. 
 
3.3. DRAK1 interacts with ANT2 outside the nucleus 
We then attempted to identify novel DRAK1 binding partners using a combination of pull-down 
assays and mass spectrometry, which is useful for identifying interacting proteins [4]. Strep-DRAK1 
or -DRAK2 was expressed in HEK293T cells, and the Strep pull-down proteins were resolved by 
SDS-PAGE followed by silver staining. To exclude non-specific binding, lysates of the cells 
transfected with an empty Strep vector were used as the negative controls. Fig. 3A shows a typical gel 
result. The specific protein bands at 31 and 60 kDa were found in the lysates of cells transfected with 
Strep-DRAK1. Because the band at 60 kDa was close to the molecular mass of Strep-DRAK1 protein, 
the band at 31 kDa was excised and analyzed by MALDI-TOF MS after in-gel tryptic digestion. The 
analysis showed that the 31-kDa protein was ANT2 (Fig. 3B). To confirm the interaction between 
DRAK1 and ANT2, we performed a Strep pull-down assay using lysates from cells expressing 
Strep-DRAK1 and the C-terminal FLAG-tagged ANT2 (ANT2-FLAG). As shown in Fig. 3C, 
Strep-DRAK1-WT specifically interacted with ANT2-FLAG. Because ANT2 localizes in the 
mitochondria, we examined the ability of DRAK1 mutants that mainly localized in the cytoplasm to 
bind to ANT2. Both S395D and K396A/R397A mutants, which localized in the cytoplasm, including 
the mitochondria, showed stronger interactions with ANT2 compared to DRAK1-WT (Fig. 3C). To 
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identify the regions of DRAK1 that are responsible for binding to ANT2, we produced various 
truncated mutants of DRAK1 as GST fusion proteins (Fig. 3D), and performed GST pull-down assays. 
We confirmed that GST-fused full-length DRAK1 (GST-DRAK1-WT) interacted with ANT2-FLAG. 
The catalytic domain (amino acids 61-321) of DRAK1 (GST-DRAK1-CD) was required for binding 
to ANT2. Notably, the binding of GST-DRAK1 to ANT2-FLAG was relatively stronger than that of 
Strep-DRAK1. Therefore, we investigated the subcellular localization of GST-DRAK1. Although 
Strep-DRAK1-WT was localized in the nucleus, GST-DRAK1-WT was localized outside the nucleus 
similar to Strep-DRAK1-K396A/R397A (Fig. 3E), resulting in stronger interaction with mitochondrial 
ANT2. Finally, we examined whether DRAK1 indirectly binds to ANT2 through an interaction with 
mitochondrial outer-membrane protein VDAC, because ANT2 is a mitochondrial inner-membrane 
protein. As shown in Fig. 3F, Strep-DRAK1 failed to interact with VDAC, although it interacted with 
endogenous ANT2. These results suggest that DRAK1 might directly interact with ANT2 at the 
mitochondria. 
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4. Discussion 
The dynamic subcellular localization of many signaling molecules plays a pivotal role in their 
function. In the present study, we demonstrated that DRAK1 was exclusively localized in the nucleus 
and translocated into the cytosol, including the mitochondria, in response to PKC activation in U2OS 
cells (Fig. 4). DRAK1 contains two NLS sequences, one in the catalytic domain (93RKRRKG) and one 
near the C terminus (395SKRFK). A previous study reveals that DRAK2 also localizes in the nucleus 
through NLS (350SKRFR in rat) in its C terminus, and PKC induces the translocation of DRAK2 into 
the cytoplasm by phosphorylating DRAK2 at Ser350 [15]. DRAK2 has an amino acid sequence highly 
similar to that of DRAK1 (52% identity, 83% similarity). However, although DRAK1 interacted with 
p53, DRAK2 did not. DRAK1 contains a proline-rich region (30PCRPPPPP) in the N terminus, 
although its role remains unclear. Generally, the proline-rich region is involved in protein-protein 
interactions [16]. For example, Src homology (SH)-3 and WW domains associate with specific 
proline-rich sequences. p53 also has the proline-rich domain, which contains 14 prolines and 5 repeats 
of the PXXP motif, a binding site for SH3 domains [16]. It has also been shown that the proline-rich 
domain of p53 is necessary for apoptosis and efficient growth suppression elicited by p53 [17]. Taken 
together, DRAK1 might directly or indirectly interact with p53 through the proline-rich region. 
We also showed that cisplatin induced the expression of both p53 and DRAK1 in U2OS cells. 
Apoptosis-related genes, such as Bax, are transcriptionally induced by p53, which is activated by DNA 
damage and oncogenes. A previous study observed that p53 directly binds to an upstream element in 
DRAK1 and induces DRAK1 expression [6]. More importantly, cisplatin-induced phosphorylation of 
p53 at Ser392 was reduced by DRAK1 knockdown, although the total amount of p53 did not change. 
Furthermore, cisplatin-induced p53 promoter activity was decreased by DRAK1 knockdown. These 
results suggested that DRAK1 might modulate the transcriptional activity of p53 and p53-mediated 
apoptosis through a positive-feedback loop. It is still unknown whether DRAK1 directly 
phosphorylates p53 at Ser392, the site that is directly phosphorylated by a few kinases, including CK2 
[8]. The amino acid sequence surrounding Ser392 of p53 (KTEGPD392SD) does not conform to the 
consensus phosphorylation sequence for the DAPK family members. However, it is possible that 
DRAK1 phosphorylates p53 at Thr18 and Ser20 (LSQE18TF20SDL), although neither site conforms to 
13 
 
the consensus phosphorylation sequence [18]. Further studies will reveal whether DRAK1 could 
directly or indirectly activate p53. 
Furthermore, we identified ANT2 as a DRAK1 binding partner. Mitochondrial inner-membrane 
protein ANT2 regulates mitochondrial membrane permeability together with mitochondrial 
outer-membrane protein VDAC. Although we hypothesized that DRAK1 indirectly binds to ANT2 
through an interaction with VDAC, we found that DRAK1 did not associate with VDAC, suggesting 
that DRAK1 might translocate across the mitochondrial outer membrane and interact directly with 
ANT2. ANT1 and ANT3 transport ATP from the mitochondria into the cytoplasm, whereas ANT2, 
which is highly expressed in tumor cells, could import glycolytically produced ATP into the 
mitochondrial matrix [19]. It has been shown that ANT2 knockdown in human breast cancer cells 
induces apoptosis and inhibits tumor growth through the upregulation of proapoptotic protein Bax and 
the downregulation of antiapoptotic protein Bcl-xL [20]. These suggest that ANT2 exhibits an 
antiapoptotic function in cancer cells by inhibiting mitochondrial membrane permeabilization [19, 20]. 
Because ANT1-mediated ADP/ATP exchange is regulated by the Src-mediated tyrosine 
phosphorylation of ANT1 [21], DRAK1 might induce apoptosis by regulating ANT2 activity through 
its interaction and phosphorylation. On the other hand, p53 also translocates into the mitochondria in 
response to cell-death stimuli [22]. Translocated mitochondrial p53 can induce permeabilization of the 
outer mitochondrial membrane by forming complexes with the protective Bcl-xL and Bcl-2, resulting 
in cytochrome c release into the cytoplasm. We still need to elucidate how DRAK1 translocates across 
the mitochondrial outer membrane and binds to ANT2, and determine the physiological significance 
of the interaction between DRAK1 and ANT2. 
In conclusion, we demonstrated that DRAK1 was localized mainly in the nucleus and 
translocated outside the nucleus in response to PKC activation. In the nucleus, DRAK1 bound to p53 
and positively controlled its transcriptional activity, suggesting that these two proteins have the 
potential to coordinate signaling through positive-feedback regulation. In the mitochondria, DRAK1 
interacted with ANT2. Because ANT2 acts as an antiapoptotic oncoprotein, DRAK1 might be 
involved in the regulation of apoptosis through its interaction with ANT2. These findings contribute to 
the elucidation of the apoptotic signaling transduction pathway and to the development of more 
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effective anticancer agents. Further studies could reveal the mechanism by which apoptosis is 
regulated by the interaction between DRAK1 and p53 and/or ANT2. 
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Figure legends 
Fig. 1. Subcellular localization of DRAK1 in U2OS cells. (A) Schematic representations of DRAK1. 
(B and C) U2OS cells were transfected with Strep-DRAK1-WT or its mutants in the presence or 
absence of mitochondria-targeted mKeima-Red expression plasmid (mito-Red). After 20 hours, cells 
were serum-starved for 5 hours and treated with 100 nM PMA or DMSO for 60 min (C). After fix and 
permeabilization, cells were incubated with anti-Strep antibody, followed by AlexaFluor 
488-conjugated secondary antibody. All images were obtained using 40× objective lens of IN Cell 
Analyzer 6000. (D) U2OS cells expressing Strep-DRAK1-WT or -S395A were stimulated with 50 nM 
PMA for 60 min. Cell lysates were pulled down with Strep-Tactin Sepharose, followed by 
immunoblotting with anti-phospho-(Ser) PKC substrate antibody. All experiments were performed 
multiple times with similar results. 
 
Fig. 2. Regulation of p53 activity by DRAK1 in cisplatin-treated U2OS cells. (A) U2OS cells were 
transfected with Strep-DRAK1-WT and FLAG-p53. After fix, cells were incubated with anti-Strep 
antibody and anti-FLAG antibody, followed by AlexaFluor 488 and 555-conjugated secondary 
antibodies. (B) U2OS cells transfected with Strep-DRAK1-WT or -S395D were treated with 30 μM 
cisplatin or DMF for 24 hours. The cell lysates were subjected to the pull-down assay and 
immunoblotting with an anti-p53 antibody. (C) U2OS cells expressing Strep-DRAK1 or 
Strep-DRAK2 were treated with 30 μM cisplatin for 24 hours. The cell lysates were used in pull-down 
assay. (D) U2OS cells were transfected with negative control siRNA (siNC) or DRAK1 siRNA 
(siDRAK1). After 24 hours, the cells were treated with 0, 10, or 30 μM cisplatin for 24 hours. The cell 
lysates were subjected to immunoblot analysis. The levels of total p53 and phosphorylated p53 were 
normalized to GAPDH levels. The values obtained from the negative control siRNA-transfected cells 
treated with 30 μM cisplatin were taken as 100%. (E) U2OS cells were transfected with negative 
control siRNA or DRAK1 siRNA, followed by transfection with the p53-responsive reporter plasmid 
and pCMV-β-gal. The cells were treated with 30 μM cisplatin for 24 hours. After harvest, luciferase 
and β-galactosidase activities were measured, and the luciferase activity was normalized to the 
β-galactosidase activity. All data are presented as the mean ± standard error derived from at least three 
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independent experiments, and statistical analysis was performed by one-way ANOVA with Tukey’s 
multiple comparison test. 
 
Fig. 3. DRAK1 interacts with ANT2 outside the nucleus. (A) HEK293T cells transfected with Strep 
empty vector, Strep-DRAK1, or Strep-DRAK2, were scraped and used in a Strep pull-down assay. 
The bound proteins were resolved by SDS-PAGE, followed by silver staining. (B) Tryptic fragments 
of human ANT2 identified by MALDI-TOF MS. (C) HEK293T cells were transfected with 
Strep-DRAK1-WT or its mutants (Strep-DRAK1-S395D and -K396A/R397A) together with 
ANT2-FLAG. The cell lysates were used in a Strep pull-down assay. (D) HEK293T cells were 
transfected with GST-DRAK1-WT or its mutants (DRAK1-N, -ΔC, and -CD) together with 
ANT2-FLAG. The cell lysates were pulled down with glutathione Sepharose and analyzed by 
immunoblotting. (E) U2OS cells were transfected with Strep-tagged or GST-tagged DRAK1-WT and 
its mutant (DRAK1-K396A/R397A). Cells were fixed and stained with antibodies against Strep and 
GST, followed with AlexaFluor 488-conjugated secondary antibody. (F) HEK293T cells were 
transfected with Strep-DRAK1-WT or its mutants. The cell lysates were used in a Strep pull-down 
assay. All experiments were performed multiple times with similar results. 
 
Fig. 4. Proposed model of the DRAK1 signaling pathway. p53 RE, p53-responsive element. 
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